Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo - PubMed (original) (raw)
Case Reports
Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo
H N Ginsberg et al. J Clin Invest. 1986 Nov.
Abstract
Previous data suggest that apolipoprotein (apo) CIII may inhibit both triglyceride hydrolysis by lipoprotein lipase (LPL) and apo E-mediated uptake of triglyceride-rich lipoproteins by the liver. We studied apo B metabolism in very low density (VLDL), intermediate density (IDL), and low density lipoproteins (LDL) in two sisters with apo CIII-apo AI deficiency. The subjects had reduced levels of VLDL triglyceride, normal LDL cholesterol, and near absence of high density lipoprotein (HDL) cholesterol. Compartmental analysis of the kinetics of apo B metabolism after injection of 125I-VLDL and 131I-LDL revealed fractional catabolic rates (FCR) for VLDL apo B that were six to seven times faster than normal. Simultaneous injection of [3H]glycerol demonstrated rapid catabolism of VLDL triglyceride. VLDL apo B was rapidly and efficiently converted to IDL and LDL. The FCR for LDL apo B was normal. In vitro experiments indicated that, although sera from the apo CIII-apo-AI deficient patients were able to normally activate purified LPL, increasing volumes of these sera did not result in the progressive inhibition of LPL activity demonstrable with normal sera. Addition of purified apo CIII to the deficient sera resulted in 20-50% reductions in maximal LPL activity compared with levels of activity attained with the same volumes of the native, deficient sera. These in vitro studies, together with the in vivo results, indicate that in normal subjects apo CIII can inhibit the catabolism of triglyceride-rich lipoproteins by lipoprotein lipase.
Similar articles
- Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.
Aalto-Setälä K, Fisher EA, Chen X, Chajek-Shaul T, Hayek T, Zechner R, Walsh A, Ramakrishnan R, Ginsberg HN, Breslow JL. Aalto-Setälä K, et al. J Clin Invest. 1992 Nov;90(5):1889-900. doi: 10.1172/JCI116066. J Clin Invest. 1992. PMID: 1430212 Free PMC article. - Influence of obesity on the metabolism of apolipoprotein B in humans.
Egusa G, Beltz WF, Grundy SM, Howard BV. Egusa G, et al. J Clin Invest. 1985 Aug;76(2):596-603. doi: 10.1172/JCI112011. J Clin Invest. 1985. PMID: 4031064 Free PMC article. - Presence of Apo B48, and relative Apo CII deficiency and Apo CIII enrichment in uremic very-low density lipoproteins.
Atger V, Beyne P, Frommherz K, Roullet JB, Drüeke T. Atger V, et al. Ann Biol Clin (Paris). 1989;47(8):497-501. Ann Biol Clin (Paris). 1989. PMID: 2690681 Review. - In vivo studies of VLDL metabolism and LDL heterogeneity.
Demant T, Packard C. Demant T, et al. Eur Heart J. 1998 Jul;19 Suppl H:H7-10. Eur Heart J. 1998. PMID: 9717058 Review.
Cited by
- Macromolecular Interactions of Lipoprotein Lipase (LPL).
Wheless A, Gunn KH, Neher SB. Wheless A, et al. Subcell Biochem. 2024;104:139-179. doi: 10.1007/978-3-031-58843-3_8. Subcell Biochem. 2024. PMID: 38963487 Review. - Apolipoprotein B Secretion Assay from Primary Hepatocytes.
Wang Y, Li X, Huang R, Chen XW, Wang X. Wang Y, et al. Bio Protoc. 2024 May 5;14(9):e4982. doi: 10.21769/BioProtoc.4982. eCollection 2024 May 5. Bio Protoc. 2024. PMID: 38737509 Free PMC article. - Apolipoprotein-CIII _O_-Glycosylation, a Link between GALNT2 and Plasma Lipids.
Naber A, Demus D, Slieker R, Nicolardi S, Beulens JWJ, Elders PJM, Lieverse AG, Sijbrands EJG, 't Hart LM, Wuhrer M, van Hoek M. Naber A, et al. Int J Mol Sci. 2023 Oct 2;24(19):14844. doi: 10.3390/ijms241914844. Int J Mol Sci. 2023. PMID: 37834292 Free PMC article. - Monoclonal Antibodies, Gene Silencing and Gene Editing (CRISPR) Therapies for the Treatment of Hyperlipidemia-The Future Is Here.
Hermel M, Lieberman M, Slipczuk L, Rana JS, Virani SS. Hermel M, et al. Pharmaceutics. 2023 Jan 30;15(2):459. doi: 10.3390/pharmaceutics15020459. Pharmaceutics. 2023. PMID: 36839781 Free PMC article. Review. - New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3.
Kim JY, Kim NH. Kim JY, et al. J Lipid Atheroscler. 2023 Jan;12(1):23-36. doi: 10.12997/jla.2023.12.1.23. Epub 2022 Nov 7. J Lipid Atheroscler. 2023. PMID: 36761060 Free PMC article. Review.
References
- J Lipid Res. 1969 May;10(3):341-4 - PubMed
- J Biol Chem. 1951 Nov;193(1):265-75 - PubMed
- Biochem Biophys Res Commun. 1972 Jan 31;46(2):375-82 - PubMed
- Biochim Biophys Acta. 1972 Feb 21;260(2):212-21 - PubMed
- J Biol Chem. 1975 Jun 25;250(12):4505-11 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources